Bonus issue alert! Multibagger Titan Biotech announces its maiden 1:4 bonus issue

Biological products manufacturer Titan Biotech on Thursday announced its maiden bonus issue in a 1:4 ratio, rewarding shareholders after the stock gained more than 200% in a year.

The company, which makes collagen, skincare, bone and joint care ingredients, proteins and animal nutrition products, said its board approved issuing one bonus share of Rs 2 face value for every four shares held on the record date, subject to shareholders’ approval at the upcoming AGM.

A bonus issue consists of free shares distributed by a company from its reserves and is often seen as a sign of strong financial health and growth prospects. While the issue of bonus shares increases the total number of outstanding shares, it does not change the company’s market capitalisation. However, it can improve liquidity and affordability, allowing more investors to add shares of the company to their portfolio.


Accordingly, Titan Biotech's board approved the plan to increase the company’s authorised capital from the existing Rs 10 crore divided into 5 crore shares to Rs 10.4 crore divided into 5.2 crore shares. The bonus shares will be issued by utilising nearly Rs 2.07 crore from the company’s free reserves and share premium, the company said, while noting that its balance of premium reserve and free reserves stood at around Rs 16,258 lakh as on March 31, 2026.

The record date to determine the eligibility of shareholders set to receive the bonus shares is yet to be announced. Only those shareholders who own shares of the company in their demat accounts as on the record date will be eligible to receive the bonus shares.

Also read | Madhusudan Kela’s portfolio: Top 5 holdings and how they performed in August

Titan Biotech share price

Titan Biotech shares jumped 5% after the announcement, trading at Rs 435.55 apiece on BSE on Thursday afternoon. The stock has gained around 13% in the past five days and 4% in the past one month. The multibagger stock has soared around 104% in 2026 so far.

Also read | Explained: What $127 billion FCNR(B) inflows mean for ICICI Bank, HDFC Bank, other bank stocks

In the longer term, Titan Biotech shares have delivered stellar returns of around 208% in the past one year and 536% over the past five years.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)